Perioperative phase II trial of fianlimab and cemiplimab in combination with chemotherapy versus cemiplimab in combination with chemotherapy in patients with resectable early-stage NSCLC (stages II to IIIB [N2]).
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: ICON CLINICAL RESEARCH LTD
- Phase: II
- Execution start: 26/11/2024
- End of execution: 03/06/2029
- IP: JAVIER VALDIVIA BAUTISTA
